Desmoplastic small round-cell tumor (DSRCT) is a rare and highly aggressive neoplasm of children, adolescents, and young adults that begins and spreads on the peritoneal surfaces. The organ of origin is the peritoneum. Less than 200 cases are reported in the world literature. DSRCT was first described in 1989 by Gerald and Rosai and is characterized by distinct clinicopathologic features.1,2 The tumor is composed of desmoplastic stroma with nests of small round blue cells. DSRCT is associated with a characteristic chromosomal translocation, t (11; 22) (p13; q12), which fuses the N-terminus of the Ewing sarcoma (EWS) gene to the C-terminus of the Wilms tumor (WT-1) gene.3,4 The presence of this translocation provides confirmation of the diagnosis.
DSRCT has a predilection for young males in their second and third decades of life, affecting mostly adolescent males. It usually presents with diffuse and multifocal abdominal disease similar in gross appearance to carcinomatosis. It can also metastasize to different locations including the intrathoracic cavity, pleura, paratesticular, and lymph nodes. Patients presenting with abdominal disease typically are in an advanced stage, with large masses and/or extensive seeding in the visceral and parietal peritoneal layers. DSRCT, almost always, is disseminated regionally. Unless found incidentally, multiple peritoneal based lesions are always seen.
Despite multiple strategies that include several chemotherapy regimens like those active for Ewing’s sarcoma, aggressive debulking surgery, whole-abdominal radiation, high-dose chemotherapy with autologous stem cell transplant, survival for patients with DSRCT continues to be poor. Despite prolonged hospital stays and morbidity associated with these various interventions, durable remissions remain rare. DSRCT has a 15% overall survival at 5 years, with most patients experiencing resistant and recurrent disease before the end of life.5 Inclusion of DSRCT in this rare tumors registry is thus pertinent in the multi-institutional data collection and analysis that will enhance the understanding of this rare but aggressive tumor.
DSRCT typically presents as a large intra-abdominal mass with numerous smaller peritoneal implants that spread along the peritoneal and mesothelial epithelium. Patients typically are aged 5 to 25 years at presentation, and 90% are male. Symptoms include abdominal pain and/or abdominal distension and possibly nausea or emesis. Vague abdominal pain is sometimes confused with constipation, but radiographic imaging readily reveals the diagnosis. There may also be ascites with intraparenchymal metastasis to the liver. The presence of ascites is the usual cause for the abdominal distension. The lesions are usually very large in size, 8 cm or greater, with smaller 3- to 5-mm lesions coating the peritoneum and impairing absorption of normal peritoneal fluid. The smaller lesions may evade imaging. The most common site of metastases is the liver. DSCRT can also metastasize to the lungs and or lymph nodes of the groin, neck, or mediastinum. Less common nonspecific clinical findings that should raise a suspicion of DSRCT in a young male are retroperitoneal lymphadenopathy, hydronephrosis, bowel obstruction, calcifications, and nodular peritoneal thickening, especially when these findings are supported by radiographic evidence of a disseminated intra-abdominal neoplasm.3,6,7
Imaging of the abdomen with ultrasound, computed tomography (CT), or magnetic resonance imaging reveals multiple tumor nodules “studding” the peritoneal cavity (almost always more than 1 nodule). Dozens or hundreds of nodules on the diaphragm can cause indentation or “scalloping” of the liver on CT scan. Large pelvic tumors are common. Open, laparoscopic, or image-guided biopsy is appropriate. The gold standard for the diagnosis of DSRCT includes histopathology and cytogenetics. The biopsy should be evaluated by cytogenetics to confirm the characteristic translocation and EWS WT-1 fusion.
Once abdominal imaging reveals multiple tumors, imaging of the chest with CT scan and/or total-body positron emission tomography scan are necessary as part of the staging evaluation. Presently, there is no formal staging system for DSRCT, but one is being proposed and is under review that incorporates abdominal disease burden (stage 1 or 2) and sites of metastasis such as liver (stage 3) or lung (stage 4).8 The extensive peritoneal disease seen in DSRCT may be more accurately described as multifocal abdominal disease. All patients are not stage 4.
Gross examination of DSRCT reveals large tumors that usually have multiple peritoneal implants. The cut surface shows areas of necrosis and may also have myxoid changes. Typical microscopic histologic features are clusters of blue tumor cells, in a round or elongated arrangement, distributed within abundant desmoplastic/cellular stroma. Tumor cells are small to medium in size with round/oval hyperchromatic nuclei and inconspicuous nucleoli. Cytoplasm is scant. Necrotic with necrotic cells and mitosis are common findings.3,9,10 The immunohistochemical profile of DSRCT shows divergent differentiation, a distinct feature, with immunohistochemical reactivity for epithelial (keratin, epithelial membrane antigen), mesenchymal (vimentin), neural (neuron-specific enolase and CD56), and myogenic (desmin) markers. Almost all DSRCT are positive for WT1, a polyclonal antibody against the amino terminus of the WT1 protein.11,12 A high serum cancer antigen 125 level may be a useful marker for DSRCT, permitting early diagnosis and treatment.13,14 Lae et al10 in a reported series of 32 cases of DSRCTs found that 84% of cases were immunoreactive for neuron-specific enolase, 81% for desmin, and 87% for keratin. Also, 91% of cases were positive for WT1. Similar findings were reported by other studies.9,15 DSRCT can be differentiated from other small round-cell tumors like EWS/PNET, small-cell sarcoma, lymphoma, neuroblastoma, WT, rhabdomyosarcoma, and malignant mesothelioma, with the demonstration of a divergent phenotype and the reciprocal translocation characteristic of DSRCT using cytogenetic studies. Further literature is available.4,16–18
Patients with DSRCT require aggressive multimodal therapy. Current treatment protocols with neoadjuvant chemotherapy, debulking of >90% of the tumor, and radiation therapy have been reported to prolong life but rarely achieve cure. Chemotherapy agents with known activity in DSRCT are very similar to those active in EWS. Both tumors share a EWS fusion protein and may also share molecular mechanisms facilitating proliferation and survival pathways. Alkylating agents such as cyclophosphamide and ifosfamide are important components of therapy. Currently, a well-recognized treatment schema has been reported by Kushner et al19 who described results in 12 DSRCT patients. This intensive alkylator-based therapy used cyclophosphamide, doxorubicin, vincristine alternating with ifosfamide and etoposide. Its combination with other treatment modalities such as surgery, radiation, autologous stem cell rescue, or the combination of all of the above was used. The median survival time was 19 months. For those achieving complete response, the median follow-up in this series was 22 months. The toxicity for this regimen can be substantial and often includes hospitalization not only for chemotherapy, but also for fevers associated with myelosuppression and mucositis. An alternative more tolerable outpatient regimen has more recently been used for DSRCT as documented in a case report.20 In this report, neoadjuvant chemotherapy included vincristine, ifosfamide, dexrazoxane/doxorubicin, and etoposide. Continuous hyperthermic peritoneal perfusion HIPEC with cisplatin was given after extensive cytoreductive surgery. This was followed by irinotecan+temozolomide monthly×2 and then abdominal radiation 30 Gy with simultaneous temozolomide. A total of 12 cycles of irinotecan and temozolomide were given and provided a disease-free interval of nearly 2 years. It permitted routine school attendance, and play activities were possible with an excellent quality of life.
Aggressive cytoreductive surgery is currently accepted to have a primary role in the achievement of prolonged survival of other malignancies involving the peritoneum.21–23 In DSRCT, La Quaglia and Brennan6 reported that 3-year overall survival was 58% in patients with gross total resection in comparison with 0% in the nonresection cohort. Other therapeutic modalities such as CHPP, also called hyperthermic intrapertitoneal chemotherapy (HIPEC), have been found to improve outcome in carcinoma involving the peritoneum.23–26 Recently, Hayes-Jordan and colleagues were the first to report on the combined use of cytoreductive surgery and HIPEC in 2 children with DSCRT. Both children received neoadjuvant chemotherapy, followed by cytoreductive surgery and intraoperative HIPEC using cisplatin. At the time of publication, both patients had no evidence of disease 6 and 10 months postoperatively.27 Currently, a phase I trial is ongoing using HIPEC at MD Anderson Cancer Center.8 A more recent series reports a median 3 year survival of 71% with HIPEC and 29% in those receiving chemotherapy and radiotherapy alone.
Difficulty achieving complete surgical excision and thus cure makes long-term follow-up important. Imaging studies are useful in providing follow-up information on tumor remission/recurrence and directly impact patient management. Timing of follow-up is at least 3-month intervals for 3 years and then every 6 months for until 5 years after the end of therapy but will depend on patients’ disease and the managing clinicians.
DSRCT is a highly aggressive tumor that usually occurs in young adult men. Despite its well-defined clinicopathologic properties, it is often misdiagnosed and difficult to manage. The diagnosis should therefore be suspected in young men with multiple heterogeneous peritoneal soft tissue masses, as early detection may influence disease containment, improving survival. Tumor markers like serum cancer antigen 125 may also be useful for early detection in patients suspected to have DSRCT. Better understanding of the disease by clinicians will also impact on early diagnosis and improve management options. There are presently no screening or preventive measures for this disease. Clinical trials are important for the development of DSRCT-specific protocols.
1. Gerald WL, Rosai J. Case 2. Desmoplastic
small cell tumor with divergent differentiation. Pediatr Pathol. 1989;9:177–183
2. Ordonez NG. Desmoplastic
small round cell tumor: I: a histopathologic study of 39 cases with emphasis on unusual histological patterns. Am J Surg Pathol. 1998;22:1303–1313
3. Gerald WL, Ladanyi M, de Alava E, et al. Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic
small round-cell tumor and its variants. J Clin Oncol. 1998;16:3028–3036
4. Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic
small round cell tumor. Cancer Res. 1994;54:2837–2840
5. Lal DR, Su WT, Wolden SL, et al. Results of multimodal treatment for desmoplastic
small round cell tumors. J Pediatr Surg. 2005;40:251–255
6. Quaglia MP, Brennan MF. The clinical approach to desmoplastic
small round cell tumor. Surg Oncol. 2000;9:77–81
7. Gil A, Gomez Portilla A, Brun EA, et al. Clinical perspective on desmoplastic
small round-cell tumor. Oncology. 2004;67:231–242
8. 2005-0917 N. A Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Doses of Cisplatin for Children
With Peritoneal Carcinomatosis or Advanced Peritoneal and Retroperitoneal Disease. In: Center UTMDAC, ed
9. Gerald WL, Miller HK, Battifora H, et al. Intra-abdominal desmoplastic
small round-cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals. Am J Surg Pathol. 1991;15:499–513
10. Lae ME, Roche PC, Jin L, et al. Desmoplastic
small round cell tumor: a clinicopathologic, immunohistochemical, and molecular study of 32 tumors. Am J Surg Pathol. 2002;26:823–835
11. Hill DA, Pfeifer JD, Marley EF, et al. WT1 staining reliably differentiates desmoplastic
small round cell tumor from Ewing sarcoma
/primitive neuroectodermal tumor. An immunohistochemical and molecular diagnostic study. Am J Clin Pathol. 2000;114:345–353
12. Zhang PJ, Goldblum JR, Pawel BR, et al. Immunophenotype of desmoplastic
small round cell tumors as detected in cases with EWS-WT1 gene fusion product. Mod Pathol. 2003;16:229–235
13. Yoshizawa J, Maie M, Eto T, et al. A case of intra-abdominal desmoplastic
small-round-cell tumor with elevated serum CA125. Pediatr Surg Int. 2002;18:238–240
14. Fizazi K, Farhat F, Theodore C, et al. Ca125 and neuron-specific enolase (NSE) as tumour markers for intra-abdominal desmoplastic
small round-cell tumours. Br J Cancer. 1997;75:76–78
15. Biswas G, Laskar S, Banavali SD, et al. Desmoplastic
small round cell tumor: extra abdominal
presentations and the results of treatment. Indian J Cancer. 2005;42:78–84
16. Rodriguez E, Sreekantaiah C, Gerald W, et al. A recurring translocation, t(11;22)(p13;q11.2), characterizes intra-abdominal desmoplastic
small round-cell tumors. Cancer Genet Cytogenet. 1993;69:17–21
17. Al-Nafussi A. Practical morphological approach to the diagnosis and differential diagnosis of soft tissue sarcomas. Curr Diagn Pathol. 2002;8:395–411
18. Devoe K, Weidner N. Immunohistochemistry of small round-cell tumors. Semin Diagn Pathol. 2000;17:216–224
19. Kushner BH, LaQuaglia MP, Wollner N, et al. Desmoplastic
small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol. 1996;14:1526–1531
20. Aguilera D, Hayes-Jordan A, Anderson P, et al. Outpatient and home chemotherapy with novel local control strategies in desmoplastic
small round cell tumor. Sarcoma
21. Sugarbaker PH. A curative approach to peritoneal carcinomatosis from colorectal cancer. Semin Oncol. 2005;32(6 suppl 9):S68–S73
22. Sugarbaker PH, Stuart OA, Yoo D. Strategies for management of the peritoneal surface component of cancer: cytoreductive surgery plus perioperative intraperitoneal chemotherapy. J Oncol Pharm Pract. 2005;11:111–119
23. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221:124–132
24. Glehen O, Gilly FN, Sugarbaker PH. New perspectives in the management of colorectal cancer: what about peritoneal carcinomatosis? Scand J Surg. 2003;92:178–179
25. Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg. 1994;219:112–119
26. Glehen O, Mithieux F, Osinsky D, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal
cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol. 2003;21:799–806
27. Hayes-Jordan A, Anderson P, Curley S, et al. Continuous hyperthermic peritoneal perfusion for desmoplastic
small round cell tumor. J Pediatr Surg. 2007;42:E29–E32